Treatment with recombinant tissue-type plasminogen activator increased the odds of symptomatic intracranial hemorrhage by a greater amount in patients taking prior antiplatelets than those who were not ( P = 0.019 for test of interaction ) , but had no clear detrimental effect on functional outcome at 6 months in this group ( P = 0.781 for test of interaction ) .